SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI5/14/2017 6:31:41 PM
   of 3027
 
MNTA ‘ReadMeFirst’ updated:

2017-2018 news flow;
reasons to be optimistic;
1Q17 financial results, liquidity, and diluted share count;
transcript of 1Q17 CC;
phase-3 trial of M923 meets FDA draft guidelines for interchange FoBs;
incoming FDA commissioner (Scott Gottlieb) emphasizes interchangeable FoBs;
an interchangeable Humira FoB for US market is badly needed (chart).

 investorshub.advfn.com

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News